Acute Respiratory Distress Syndrome – Landscape & Forecast – Disease Landscape & Forecast
ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-threatening owing to respiratory failure and/or multi-organ dysfunction. ARDS may be caused by sepsis, trauma, severe pneumonia, or inhalation of harmful substances and it is associated with a high mortality rate. No pharmacological therapy is specifically approved for ARDS and treatment is supportive, principally comprising nonpharmacological approaches (e.g., mechanical ventilation, oxygen supplementation). There is unmet need and thus commercial opportunity for effective pharmacotherapies that can reduce patients’ reliance on ventilation and the mortality associated with ARDS. There are no therapies in late stages of development for ARDS, and the pipeline comprises largely early- to mid-stage agents with diverse mechanisms of action (e.g., Apeptico/Mediolanum Farmaceutici’s sodium channel modulator solnatide).
QUESTIONS ANSWERED
- How will the size of the ARDS population change through 2026?
- What are the key drug targets emerging from basic and clinical research in ARDS? Which emerging therapies do ARDS experts consider most promising? How would new therapies influence management of ARDS patients?
- How are emerging ARDS drugs being evaluated, and which are likely to launch by 2026? What commercial impact will they have on the ARDS market?
PRODUCT DESCRIPTION
Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Table of contents
- Acute Respiratory Distress Syndrome - Landscape & Forecast - Disease Landscape & Forecast
- Executive Summary
- Commercial Outlook
- Forecast
- Epidemiology Overview
- Current Treatment Overview
- Key Findings
- Diagnosis
- Treatment Goals
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Therapies Used for Acute Respiratory Distress Syndrome
- Current Treatments Used for Acute Respiratory Distress Syndrome
- Market Events Impacting the Use of Key Current Therapies in Acute Respiratory Distress Syndrome
- Noninvasive Mechanical Ventilation
- Invasive Mechanical Ventilation
- Nonpharmacological Rescue Therapies for Acute Respiratory Distress Syndrome
- Corticosteroids
- Medical Practice
- Etiology and Pathophysiology
- Key Findings
- Etiology of Acute Respiratory Distress Syndrome
- Pathophysiology of Acute Respiratory Distress Syndrome
- Disease Definition and Classification of Acute Respiratory Distress Syndrome
- Clinical Presentation, Symptomatology, and Complications of Acute Respiratory Distress Syndrome
- Key Pathways and Drug Targets
- Unmet Need Overview
- Emerging Therapies Overview
- Access & Reimbursement Overview
- Methodology
- Bottom-Up Forecasting Overview
- Bottom-Up Forecast Assumptions
- General Sources of Data
- Drug Treatment Rate Assumptions in Acute Respiratory Distress Syndrome
- Patient Share Assumptions in Acute Respiratory Distress Syndrome
- General Statements About Pricing
- Sources for Drug Prices
- 2016 Exchange Rates
- Price per Treated Day: 2026
- Dosing, Days of Therapy, and Compliance
- Out-Year Forecasting
- Emerging Therapy Prices
- Primary Market Research
- Appendix
Akash Saini, M.Sc., Ph.D., is the manager of the China In-Depth team at Clarivate. In this role, he leads the efforts to create syndicated landscape and forecast content on various therapy areas for the Chinese market. Previously, he was an assistant manager at BioXcel, where he led consulting projects based on in-silico drug discovery and identification of drug repurposing and in-licensing opportunities. Dr. Saini received his Ph.D. in biochemistry and biotechnology from the International Centre for Genetic Engineering and Biotechnology in New Delhi and conducted postdoctoral research at the University of Massachusetts Medical School. He earned his M.Sc. in biotechnology from Jawaharlal Nehru University in India.